Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as *CYP2C9**3*3

Tobias Bäckström · Gunilla Barkman ·
Jonatan D. Lindh · Erik Eliasson

Received: 8 May 2009 / Accepted: 16 May 2009 / Published online: 30 May 2009
© Springer-Verlag 2009

Sir, an 86-year-old woman suffering from cardiovascular disease and atrial fibrillation treated with warfarin was admitted to the emergency department following self-inflicted intoxication with warfarin. Her GP had instituted a dementia workup due to episodes of confusion, and during a confusional episode the patient ingested a “large number” of warfarin tablets. When she was admitted to the emergency department approximately 12 h later, she had a PK-INR of 2.2 and was initially treated with Ocplex (factor II, VII, IX, X, protein C, protein S) as well as vitamin K. During the first 8 days, she received 20 mg/day of vitamin K i.v. and her PK-INR was stable around 2.2. The ninth day after admission, no vitamin K was administered upon which her PK-INR increased to 4.6, and vitamin K treatment was reinstated. Her maintenance dose of warfarin had been low (5–7.5 mg/week) during warfarin treatment, and a lowered warfarin elimination caused by genetic polymorphism was suspected. Genotyping confirmed a genotype associated with a low clearance of warfarin (*CYP2C9**3*3). The low maintenance dose of warfarin seen in this patient is in accord with doses seen in most *CYP2C9**3*3 patients described in the literature [1]. Twenty-five days after warfarin intake, the PK-INR was still elevated (1.4) despite ongoing vitamin K treatment.

S-warfarin, the more potent enantiomer of racemic warfarin, is metabolised by the *CYP2C9* enzyme, and polymorphisms in

the *CYP2C9* gene may cause a reduced clearance [2, 3]. In patients who are homozygous for *CYP2C9**3 it has been shown that the clearance of s-warfarin can be reduced by 90%, which would correspond to a 10-fold increase in the normal s-warfarin half-life of 18–35 h [4, 5].

To our knowledge, this is the first report on self-inflicted intoxication with warfarin by an individual with a *CYP2C9* genotype predisposing to slow warfarin elimination. The observed long recovery period with daily vitamin K treatment suggests that *CYP2C9* genotyping in cases of warfarin intoxication may help to better understand the time requirements for adequate monitoring.

Acknowledgements This contribution was supported by grants from The Swedish Research Council (#4496).

References

1. Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of *CYP2C9* genotype on warfarin dose requirements - a systematic review and meta-analysis. *Eur J Clin Pharmacol* 65(4):365–375
2. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of *CYP2C9*. *Pharmacogenetics* 4:39–42
3. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the *CYP2C9*-Leu359 allelic variant in the tolbutamide polymorphism. *Pharmacogenetics* 6:341–9
4. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padriani R (2002) Influence of *CYP2C9* and *CYP2C19* genetic polymorphisms on warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 72:702–710
5. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H (1998) Comparisons between in-vitro and in-vivo metabolism of (s)-warfarin: catalytic activities of cDNA-expressed *CYP2C9*, its leu₃₅₉ variant and their mixture versus unbound clearance in patients with the corresponding *CYP2C9* genotypes. *Pharmacogenetics* 8:365–373

T. Bäckström (✉) · J. D. Lindh · E. Eliasson
Department of Laboratory Medicine, Division of Clinical
Pharmacology, Karolinska Institutet,
S-141 86 Stockholm, Sweden
e-mail: tobias.backstrom@karolinska.se

G. Barkman
Department of Geriatrics, Dalens Hospital,
Stockholm, Sweden